Inovio Pharmaceuticals Inc (INO) - Total Assets
Based on the latest financial reports, Inovio Pharmaceuticals Inc (INO) holds total assets worth $69.39 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore INO operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Inovio Pharmaceuticals Inc - Total Assets Trend (1998–2024)
This chart illustrates how Inovio Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. See Inovio Pharmaceuticals Inc (INO) shareholders funds for net asset value and shareholders' equity analysis.
Inovio Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Inovio Pharmaceuticals Inc's total assets of $69.39 Million consist of 86.4% current assets and 13.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 58.1% |
| Accounts Receivable | $1.20 Million | 1.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1998–2024)
This chart illustrates how Inovio Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Inovio Pharmaceuticals Inc worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Inovio Pharmaceuticals Inc's current assets represent 86.4% of total assets in 2024, an increase from 77.6% in 1998.
- Cash Position: Cash and equivalents constituted 58.1% of total assets in 2024, down from 63.3% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 10.0% in 1998.
- Asset Diversification: The largest asset category is accounts receivable at 1.1% of total assets.
Inovio Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Inovio Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Uniqure NV
NASDAQ:QURE
|
USA | $888.38 Million |
|
Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI
|
USA | $571.00K |
|
Kura Oncology Inc
NASDAQ:KURA
|
USA | $652.55 Million |
|
Bioventix
LSE:BVXP
|
UK | GBX13.03 Million |
|
Barinthus Biotherapeutics plc
NASDAQ:BRNS
|
USA | $109.20 Million |
|
Third Harmonic Bio Inc.
NASDAQ:THRD
|
USA | $279.84 Million |
|
Suzhou Fushilai Pharmaceutical Co. Ltd.
SHE:301258
|
China | CN¥2.13 Billion |
|
Enveric Biosciences Inc
NASDAQ:ENVB
|
USA | $4.36 Million |
Inovio Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.79 | 3.88 | 11.30 |
| Quick Ratio | 0.79 | -3680.35 | 11.30 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-14.64 Million | $67.79 Million | $429.46 Million |
Inovio Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Inovio Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.58 |
| Latest Market Cap to Assets Ratio | 0.64 |
| Asset Growth Rate (YoY) | -33.8% |
| Total Assets | $113.20 Million |
| Market Capitalization | $72.83 Million USD |
Valuation Analysis
Below Book Valuation: The market values Inovio Pharmaceuticals Inc's assets below their book value (0.64x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Inovio Pharmaceuticals Inc's assets decreased by 33.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Inovio Pharmaceuticals Inc (1998–2024)
The table below shows the annual total assets of Inovio Pharmaceuticals Inc from 1998 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $113.20 Million | -33.78% |
| 2023-12-31 | $170.95 Million | -50.95% |
| 2022-12-31 | $348.53 Million | -29.72% |
| 2021-12-31 | $495.94 Million | -8.12% |
| 2020-12-31 | $539.77 Million | +274.97% |
| 2019-12-31 | $143.95 Million | +9.79% |
| 2018-12-31 | $131.11 Million | -29.98% |
| 2017-12-31 | $187.24 Million | +7.79% |
| 2016-12-31 | $173.71 Million | -18.77% |
| 2015-12-31 | $213.84 Million | +62.26% |
| 2014-12-31 | $131.79 Million | +49.27% |
| 2013-12-31 | $88.29 Million | +95.59% |
| 2012-12-31 | $45.14 Million | -26.13% |
| 2011-12-31 | $61.11 Million | +8.99% |
| 2010-12-31 | $56.07 Million | -30.46% |
| 2009-12-31 | $80.63 Million | +106.81% |
| 2008-12-31 | $38.99 Million | -1.98% |
| 2007-12-31 | $39.78 Million | +10.64% |
| 2006-12-31 | $35.95 Million | +24.05% |
| 2005-12-31 | $28.98 Million | +38.31% |
| 2004-12-31 | $20.95 Million | +29.10% |
| 2003-12-31 | $16.23 Million | +199.47% |
| 2002-12-31 | $5.42 Million | -18.31% |
| 2001-12-31 | $6.63 Million | -42.25% |
| 2000-12-31 | $11.49 Million | -18.03% |
| 1999-12-31 | $14.01 Million | +42.98% |
| 1998-12-31 | $9.80 Million | -- |
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA s… Read more